Emerald Advisers’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Emerald Advisers’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,635	Closed	-$271K	–	249
2023 Q2	$271K	Buy	+2,635	New	+$278K	0.01%	202
2022 Q4	–	Sell	-23,478	Closed	-$1.45M	–	269
2022 Q3	$1.45M	Sell	23,478 -8,526	-27%	-$596K	0.08%	129
2022 Q2	$2.55M	Buy	32,004 +1,482	+5%	+$140K	0.13%	116
2022 Q1	$3.21M	Buy	30,522 +1,083	+4%	+$106K	0.12%	122
2021 Q4	$3.17M	Sell	29,439 -2,406	-8%	-$262K	0.12%	126
2021 Q3	$3.49M	Sell	31,845 -839	-3%	-$87.1K	0.13%	120
2021 Q2	$3.06M	Hold	32,684	–	–	0.11%	126
2021 Q1	$3.01M	Sell	32,684 -17,440	-35%	-$1.47M	0.11%	124
2020 Q4	$3.67M	Sell	50,124 -589,441	-92%	-$43.8M	0.12%	125
2020 Q3	$49.7M	Sell	639,565 -225,325	-26%	-$15.5M	2.04%	5
2020 Q2	$48.1M	Sell	864,890 -360,306	-29%	-$15.4M	2.09%	3
2020 Q1	$36.3M	Buy	1,225,196 +18,262	+2%	+$618K	2.1%	5
2019 Q4	$43.7M	Sell	1,206,934 -625	-0.1%	-$19.2K	1.85%	6
2019 Q3	$32.9M	Sell	1,207,559 -103,519	-8%	-$2.68M	1.54%	16
2019 Q2	$31.5M	Sell	1,311,078 -18,116	-1%	-$460K	1.27%	25
2019 Q1	$35.1M	Buy	1,329,194 +389,718	+41%	+$9.23M	1.43%	15
2018 Q4	$18.4M	Buy	+939,476	New	+$18.4M	0.9%	43
2016 Q3	–	Sell	-204,797	Closed	-$3.37M	–	330
2016 Q2	$3.37M	Buy	204,797 +99,679	+95%	+$1.61M	0.16%	155
2016 Q1	$1.74M	Buy	+105,118	New	+$1.84M	0.08%	208
2015 Q2	–	Sell	-424,266	Closed	-$12.5M	–	389
2015 Q1	$12.5M	Sell	424,266 -511,389	-55%	-$9.37M	0.63%	49
2014 Q4	$12.1M	Buy	935,655 +238,522	+34%	+$2.99M	0.64%	48
2014 Q3	$8.56M	Sell	697,133 -210,458	-23%	-$2.45M	0.51%	65
2014 Q2	$14.4M	Buy	907,591 +90,181	+11%	+$1.29M	0.81%	28
2014 Q1	$12.4M	Buy	+817,410	New	+$9.23M	0.7%	36

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Emerald Advisers's HZNP Position: Q3 2023 in Review

Emerald Advisers sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 2,635 shares — an estimated $271K sold.

Emerald Advisers first reported a position in HZNP in Q1 2014 and held it in 24 quarters. The position peaked at $49.7M in Q3 2020. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Emerald Advisers reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Emerald Advisers sold 2,635 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $271K.
Emerald Advisers first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 24 quarters.
Emerald Advisers's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $49.7M in Q3 2020.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Emerald Advisers's 13F filing for Q3 2023, filed 26 Oct 2023.